SynthesisClinical and experimental medicine2025
Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis.
Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Utilization of Steroid Sparing Agents for Immune-Related Adverse Events (irAEs): Management Strategies and Considerations.Current oncology reports · 2026Review
- Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides.Frontiers in immunology · 2026Review
- Infliximab asFrontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Comparative Risk of Cancer Recurrence During Treatment With Biologics: A Meta-Analysis.Gastro hep advances · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While biologics have proven to be effective in treating immune-mediated inflammatory diseases (IMIDs), the label of most biologics carries a warning regarding their use in patients with active cancer or a history of cancer. Consequently, there has been a reluctance to prescribe these medications to patients with a history of cancer, and little is known about the risk of new and/or recurrent cancer in patients with IMIDs treated with biologics and a previous cancer. This systematic review and meta-analysis searched PubMed, Embase, Cochrane Library, and Web of Science up to February 23, 2024, for studies on the risk of new and/or recurrent cancer following treatment with biologics in patients with IMIDs and a previous cancer compared to controls (PROSPERO; CRD42024516899). Controls included patients receiving non-biological or no therapy. Risk estimates were calculated with random-effects meta-analysis with I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.